No Data
No Data
Have Y-mAbs Therapeutics Insiders Been Selling Stock?
Some Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) shareholders may be a little concerned to see that the Founder, Thomas Gad, recently sold a substantial US$841k worth of stock at a price of US$12.02 per s
Y-mAbs Therapeutics(YMAB.US) Director Sells US$8,664 in Common Stock
$Y-mAbs Therapeutics(YMAB.US)$ Director Ber Gerard sold 722 shares of common stock on Jun 10, 2024 at an average price of $12 for a total value of $8,664.Source: Announcement What is statement of chan
Y-mAbs Therapeutics(YMAB.US) Officer Sells US$841.05K in Common Stock
$Y-mAbs Therapeutics(YMAB.US)$ Officer Gad Thomas sold 70,000 shares of common stock on Jun 10, 11, 2024 at an average price of $12.02 for a total value of $841.05K.Source: Announcement What is statem
Form 144 | Y-mAbs Therapeutics(YMAB.US) Officer Proposes to Sell 838.6K in Common Stocks
SEC FILLINGS DISCLOSED/ Jun 10, $Y-mAbs Therapeutics(YMAB.US)$ Officer Thomas Gad intends to sell 70,000 shares of its common stock on Jun 10, with a total market value of approximately $838.6K. Tho
With 43% Stake, Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Seems to Have Captured Institutional Investors' Interest
Express News | Y-MAbs Therapeutics Says Preclinical GD2-SADA Data Will Be Presented At Society Of Nuclear Medicine & Molecular Imaging 2024 Annual Meeting
No Data